ArticleChinese medicine2026
Bu-Shen-Tian-Jing Formula alleviates oxidative-inflammatory stress in granulosa cells of polycystic ovary syndrome through AGEs-RAGE/NOX4/NF-κB pathway.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Impact of Oxidative Stress Imbalance on Ovarian Function and Its Mechanisms.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a prevalent reproductive endocrine disorder. The traditional Chinese medicine Bu-Shen-Tian-Jing Formula (BSTJF) has demonstrated efficacy in ameliorating PCOS-related pathologies, however its therapeutic mechanisms remain incompletely understood. This study aimed to investigate the pharmacological mechanisms by which BSTJF improves ovarian microenvironment in PCOS.
methodsBSTJF-containing serum was applied to PCOS granulosa cells (GCs) in vitro for cellular functional assays and transcriptomic sequencing, combined with mass spectrometry-based identification of bioactive components. Network pharmacology and molecular docking were employed to predict multi-target mechanisms of BSTJF against PCOS. In vivo validation utilized an androgen-induced PCOS mouse model divided into five groups: control, PCOS, low-dose BSTJF, high-dose BSTJF, and FPS-ZM1 (RAGE inhibitor). The estrous cyclicity, glucose tolerance, reproductive hormones, ovarian morphology, and granulosa cell apoptosis of mice were detected. Serum inflammatory cytokines and biomarkers of oxidative stress in ovarian GCs were measured. Untargeted metabolomics was employed for comprehensive metabolic profiling in the serum of mice. Molecular analyses included AGEs-RAGE-NOX4 axis expression in GCs, paralleled by p38 MAPK phosphorylation kinetics and NF-κB p65 nuclear translocation dynamics.
resultsTranscriptomic analysis identified differentially expressed genes with significant enrichment in the AGEs-RAGE signaling pathway, revealing oxidative-inflammatory regulatory hubs (NOX4, SOD3, GPX2; TNF, TLR7, CCR2). Network pharmacology provided supports of BSTJF's multi-target engagement, demonstrating high-affinity interactions between its bioactive components and core targets. In vivo, BSTJF mirrored the RAGE inhibitor FPS-ZM1's efficacy by ameliorating PCOS phenotypes through reducing GC apoptosis, attenuating AGEs accumulation, inflammatory cytokines and state of oxidative stress, normalizing carbohydrate metabolism and lipid homeostasis, and inhibiting AGEs-RAGE-NOX4 axis activation and NF-κB nuclear translocation in ovarian GCs.
conclusionOur study indicated that BSTJF could ameliorate oxidative-inflammatory stress in ovarian GCs of PCOS through AGEs-RAGE/NOX4/NF-κB pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.